Michael A. Coplin
YOU?
Author Swipe
View article: Supplementary Figure 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Sunitinib or sorafenib in combination with rMVA-Twist- TRICOM vaccine decreased tumor burden and vascular area in the 4T1 breast cancer model.
View article: Supplementary Figure 3 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 3 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Effect of sunitinib or sorafenib in combination with rMVATwist- TRICOM vaccine on tumor compactness in the 4T1 breast cancer model.
View article: Supplementary Figure 4 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 4 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Sunitinib alone or in combination with vaccine decreased the frequency of splenic MDSCs and monocytes in tumor bearing mice.
View article: Supplementary Figure 4 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 4 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Sunitinib alone or in combination with vaccine decreased the frequency of splenic MDSCs and monocytes in tumor bearing mice.
View article: Data from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Data from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
This study investigated the effects on the tumor microenvironment (TME) of combining antiangiogenic tyrosine kinase inhibitors (TKI) with therapeutic vaccines, and in particular, how vascular changes affect tumor-infiltrating immune cells.…
View article: Supplementary Figure 3 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 3 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Effect of sunitinib or sorafenib in combination with rMVATwist- TRICOM vaccine on tumor compactness in the 4T1 breast cancer model.
View article: Supplementary Table 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Table 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Effect of sunitinib alone, rMVA-Twist-TRICOM vaccine alone, or sunitinib in combination with vaccine on the phenotype of tumor-infiltrating MDSCs and TAMs in the 4T1 breast tumor model.
View article: Data from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Data from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
This study investigated the effects on the tumor microenvironment (TME) of combining antiangiogenic tyrosine kinase inhibitors (TKI) with therapeutic vaccines, and in particular, how vascular changes affect tumor-infiltrating immune cells.…
View article: Supplementary Figure 2 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 2 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Examples of 2 different grades of tumor compactness in MC38-CEA tumors.
View article: Supplementary Figure 2 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 2 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Examples of 2 different grades of tumor compactness in MC38-CEA tumors.
View article: Supplementary Figure 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Figure 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Sunitinib or sorafenib in combination with rMVA-Twist- TRICOM vaccine decreased tumor burden and vascular area in the 4T1 breast cancer model.
View article: Data Supplement from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Data Supplement from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Supplementary Materials and Methods; Figure Legends
View article: Data Supplement from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Data Supplement from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Supplementary Materials and Methods; Figure Legends
View article: Supplementary Table 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines
Supplementary Table 1 from Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines Open
Effect of sunitinib alone, rMVA-Twist-TRICOM vaccine alone, or sunitinib in combination with vaccine on the phenotype of tumor-infiltrating MDSCs and TAMs in the 4T1 breast tumor model.